Effect of neoadjuvant chemotherapy combined with breast conserving surgery on early and middle stage breast cancer and its influences on tumor markers and quality of life
Objective To explore the effect of neoadjuvant chemotherapy combined with breast conserving surgery on early and middle stage breast cancer and its influences on tumor markers and quality of life.Methods A total of 66 patients with early and middle stage breast cancer admitted in our hospital from January 2020 to January 2023 were selected as the research objects and randomly divided into control group and observation group,with 33 cases in each group.The control group was treated with breast conserving surgery,and the observation group was treated with neoadjuvant chemotherapy combined with breast conserving surgery.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).Before treatment,there were no significant differences in the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and carbohydrate antigen 153(CA153)between the two groups(P>0.05);after treatment,the levels of CEA,CA125 and CA153 in the observation group were lower than those in the control group(P<0.05).Before treatment,there were no significant differences in the scores of each dimension of Functional Assessment of Cancer Therapy-Breast Cancer(FACT-B)between the two groups(P>0.05);after treatment,the scores of each dimension of FACT-B in the observation group were higher than those in the control group(P<0.05).Conclusion Neoadjuvant chemotherapy combined with breast conserving surgery is effective in the treatment of early and middle stage breast cancer,it can reduce the levels of tumor markers and improve the quality of life,which is worth promoting.
neoadjuvant chemotherapybreast conserving surgerybreast cancertumor markerquality of life
万方数据
维普
